JP6339581B2 - ヒト幹様細胞およびメタボロミック比率を使用した医薬品のヒト発達毒性の予測 - Google Patents

ヒト幹様細胞およびメタボロミック比率を使用した医薬品のヒト発達毒性の予測 Download PDF

Info

Publication number
JP6339581B2
JP6339581B2 JP2015540802A JP2015540802A JP6339581B2 JP 6339581 B2 JP6339581 B2 JP 6339581B2 JP 2015540802 A JP2015540802 A JP 2015540802A JP 2015540802 A JP2015540802 A JP 2015540802A JP 6339581 B2 JP6339581 B2 JP 6339581B2
Authority
JP
Japan
Prior art keywords
test compound
ratio
hslc
teratogenic
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015540802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501516A (ja
JP2016501516A5 (enExample
Inventor
スミス アラン
スミス アラン
ウエスト ポール
ウエスト ポール
パルマー ジェシカ
パルマー ジェシカ
Original Assignee
ステミナ バイオマーカー ディスカバリー， インコーポレイテッド
ステミナ バイオマーカー ディスカバリー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ステミナ バイオマーカー ディスカバリー， インコーポレイテッド, ステミナ バイオマーカー ディスカバリー， インコーポレイテッド filed Critical ステミナ バイオマーカー ディスカバリー， インコーポレイテッド
Publication of JP2016501516A publication Critical patent/JP2016501516A/ja
Publication of JP2016501516A5 publication Critical patent/JP2016501516A5/ja
Application granted granted Critical
Publication of JP6339581B2 publication Critical patent/JP6339581B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/22—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by measuring secondary emission from the material
    • G01N23/225—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by measuring secondary emission from the material using electron or ion
    • G01N23/2255—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by measuring secondary emission from the material using electron or ion using incident ion beams, e.g. proton beams
    • G01N23/2258—Measuring secondary ion emission, e.g. secondary ion mass spectrometry [SIMS]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2015540802A 2012-11-02 2013-11-01 ヒト幹様細胞およびメタボロミック比率を使用した医薬品のヒト発達毒性の予測 Active JP6339581B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261721746P 2012-11-02 2012-11-02
US61/721,746 2012-11-02
US201361827407P 2013-05-24 2013-05-24
US61/827,407 2013-05-24
PCT/US2013/067980 WO2014071137A1 (en) 2012-11-02 2013-11-01 Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomic ratios

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018091559A Division JP6581244B2 (ja) 2012-11-02 2018-05-10 ヒト幹様細胞およびメタボロミック比率を使用した医薬品のヒト発達毒性の予測

Publications (3)

Publication Number Publication Date
JP2016501516A JP2016501516A (ja) 2016-01-21
JP2016501516A5 JP2016501516A5 (enExample) 2016-11-04
JP6339581B2 true JP6339581B2 (ja) 2018-06-06

Family

ID=50628081

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015540802A Active JP6339581B2 (ja) 2012-11-02 2013-11-01 ヒト幹様細胞およびメタボロミック比率を使用した医薬品のヒト発達毒性の予測
JP2018091559A Active JP6581244B2 (ja) 2012-11-02 2018-05-10 ヒト幹様細胞およびメタボロミック比率を使用した医薬品のヒト発達毒性の予測

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018091559A Active JP6581244B2 (ja) 2012-11-02 2018-05-10 ヒト幹様細胞およびメタボロミック比率を使用した医薬品のヒト発達毒性の予測

Country Status (9)

Country Link
US (3) US20150301025A1 (enExample)
EP (1) EP2914748B1 (enExample)
JP (2) JP6339581B2 (enExample)
CN (1) CN104822843B (enExample)
CA (1) CA2888064C (enExample)
DK (1) DK2914748T3 (enExample)
HU (1) HUE043604T2 (enExample)
MX (1) MX362991B (enExample)
WO (1) WO2014071137A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016000293A (es) * 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
FI126398B (en) 2014-12-18 2016-11-15 Upm Kymmene Corp Method for chemical testing
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
CN109207551B (zh) * 2017-07-07 2023-05-26 上海睿智化学研究有限公司 一种筛选叶酸代谢相关药物的方法
US20210072230A1 (en) * 2018-03-09 2021-03-11 Stemina Biomarker Discovery, Inc. In vitro assay to predict cardiotoxicity
CN116547722A (zh) * 2020-11-30 2023-08-04 赛诺菲 剂量-反应图的图像分类
CN119667130B (zh) * 2025-02-13 2025-05-09 生态环境部华南环境科学研究所(生态环境部生态环境应急研究所) 一种基于血清组氨酸/犬尿氨酸快速评估双酚类物质暴露毒性效应的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
BRPI0611439A2 (pt) * 2005-05-13 2010-09-08 Lexicon Pharmaceuticals Inc compostos multicìclicos e métodos para uso dos mesmos
MX2008013002A (es) * 2006-04-10 2008-10-17 Wisconsin Alumni Res Found Reactivos y metodos para usar celulas madre embrionarias humanas para evaluar toxicidad de compuestos farmaceuticos y otros quimicos.
AU2011232577C1 (en) * 2010-03-22 2016-07-14 Stemina Biomarker Discovery, Inc. Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics
WO2011143609A1 (en) * 2010-05-14 2011-11-17 Deseret Biologicals, Inc. Formulations of diluted genetic material and methods for making same
US9447506B2 (en) 2012-07-30 2016-09-20 David Whitmore Cathodic protection of a concrete structure

Also Published As

Publication number Publication date
CA2888064A1 (en) 2014-05-08
EP2914748A4 (en) 2016-06-01
MX2015005476A (es) 2015-10-29
JP2016501516A (ja) 2016-01-21
DK2914748T3 (da) 2019-06-11
CA2888064C (en) 2023-05-30
US20150301025A1 (en) 2015-10-22
US10209240B2 (en) 2019-02-19
JP6581244B2 (ja) 2019-09-25
CN104822843B (zh) 2020-01-21
WO2014071137A1 (en) 2014-05-08
EP2914748A1 (en) 2015-09-09
US20190128872A1 (en) 2019-05-02
HUE043604T2 (hu) 2019-08-28
JP2018157823A (ja) 2018-10-11
EP2914748B1 (en) 2019-03-13
US20180128814A1 (en) 2018-05-10
CN104822843A (zh) 2015-08-05
MX362991B (es) 2019-03-01

Similar Documents

Publication Publication Date Title
JP6581244B2 (ja) ヒト幹様細胞およびメタボロミック比率を使用した医薬品のヒト発達毒性の予測
JP6254561B2 (ja) ヒト幹細胞様細胞及びメタボロミクスを使用した医薬のヒト発生毒性の予測
West et al. Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics
Collins et al. High throughput toxicity screening and intracellular detection of nanomaterials
Wright Muelas et al. Rational cell culture optimization enhances experimental reproducibility in cancer cells
Horgan et al. An overview of proteomic and metabolomic technologies and their application to pregnancy research
JP2013078342A (ja) ヒト胚性幹細胞を使用して薬学的化合物および他の化学物質の毒性を評価するための試薬および方法
Agarwal et al. Sperm proteomics: potential impact on male infertility treatment
Stryeck et al. Integrative metabolomics as emerging tool to study autophagy regulation
Matysiak et al. Effects of a honeybee sting on the serum free amino acid profile in humans
Gątarek et al. Integrated metabolomics and proteomics analysis of plasma lipid metabolism in Parkinson’s disease
EP3746796A1 (en) Diagnosis and treatment of autism spectrum disorders based on amine containing metabotypes
WO2021072351A1 (en) Diagnosis and treatment of autism spectrum disorders using altered ratios of metabolite concentrations
Li et al. Sperm metabolomic signatures of asthenozoospermia and teratozoospermia in Chinese reproductive-age men
EP3963323A1 (en) Diagnosis and treatment of autism spectrum disorders associated with altered metabolic pathways
Wan et al. Deep Learning-Decoded Raman Spectroscopy for Hour-Scale iPSC Pluripotency Assessment via Lipid–Protein Biomarkers
A. Thouas et al. Metabolomic profiling for selection of the most viable embryos in clinical IVF

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180410

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180510

R150 Certificate of patent or registration of utility model

Ref document number: 6339581

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250